STOCK TITAN

Medtronic announces FDA clearance of general surgery procedures for the Hugo™ robotic-assisted surgery (RAS) system

(Neutral)

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

Medtronic (NYSE: MDT) received FDA clearance to expand its Hugo robotic-assisted surgery system into general surgery procedures in the United States. The expanded 510(k) clearance covers all upper abdominal general surgical procedures, including gallbladder removal, Roux-en-Y gastric bypass, ventral hernia repair and small bowel resection. It also covers lower abdominal inguinal hernia procedures and appendectomy, expanding U.S. use beyond urology.

Medtronic said global Hugo procedure growth is running at more than twice the robotic surgery market's growth, with procedure volume on track to surpass 50,000 by its fiscal year-end. Outside the United States, general surgery represents Hugo's highest procedure growth, surpassing urology and gynecology. The system is in clinical use at a growing number of U.S. hospitals and health systems.

Loading...
Loading translation...
4 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

0 major · 0 points

Hollow bars mark forward-looking points. How the balance works

Positive

  • Moderate pointFDA clearance expands Hugo's U.S. use beyond urology into upper abdominal general surgery, inguinal hernia procedures and appendectomy.
  • Moderate pointGlobal Hugo procedure growth is running at more than twice the robotic surgery market's growth.
  • Minor point. Forward-looking: it has not happened yet and may not happen.Hugo procedure volume is on track to surpass 50,000 by Medtronic's fiscal year-end, the company said.
  • Minor pointGeneral surgery outside the U.S. represents Hugo's highest procedure growth, surpassing urology and gynecology.

Negative

  • None.

News Explained

The FDA clearance expands permitted U.S. Hugo use to procedures accounting for about 3.5 million surgeries annually—more than half of U.S. soft-tissue procedures.

Key Figures

Annual U.S. procedures covered: about 3.5 million surgeries annually Hugo procedure growth: more than two times the robotic surgery market Procedure milestone: on track to surpass 50,000 procedures
Annual U.S. procedures covered
about 3.5 million surgeries annually
Procedures included in the general surgery clearance
Hugo procedure growth
more than two times the robotic surgery market
Global Hugo RAS procedure growth
Procedure milestone
on track to surpass 50,000 procedures
Global Hugo RAS procedures by the end of the Medtronic fiscal year

Previous Fda approval Reports

1 past event · Latest: Sep 16
Same Type 1 event
  1. Sep 16

    FDA clearance

    24h Move
    -1.2%

    FDA clearance added LigaSure vessel-sealing technology to Hugo's U.S. robotic-assisted surgery portfolio.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

510(k), cholecystectomy, roux-en-y gastric bypass
3 terms
510(k) regulatory
"An expanded U.S. 510(k) extends the Hugo™ RAS system's reach"
A 510(k) is a U.S. regulatory submission that a medical device maker uses to show a new device is as safe and effective as an already-approved device, allowing the regulator to clear it for sale rather than requiring the longer, more stringent approval process. For investors, a cleared 510(k) usually means lower regulatory risk and a faster path to market, which can speed revenue generation and reduce uncertainty—similar to proving a new appliance works like a trusted existing model.
cholecystectomy medical
"including but not limited to cholecystectomy, Roux-en-Y gastric bypass"
Cholecystectomy is the surgical removal of the gallbladder, an organ that stores bile used for digestion; surgeons often remove it through a few small incisions using minimally invasive techniques. For investors, procedure volumes and trends matter because they drive revenue for hospitals, surgical device makers, imaging suppliers and insurers—similar to how demand for car repairs affects parts manufacturers and garages. Shifts in how often or how the surgery is done can signal changes in healthcare spending and technology adoption.
roux-en-y gastric bypass medical
"cholecystectomy, Roux-en-Y gastric bypass, ventral hernia"
A roux-en-y gastric bypass is a surgical weight-loss procedure that makes the stomach smaller and reroutes the small intestine so food bypasses part of the digestive tract, like shortening and rerouting a plumbing line to change flow. Investors care because it drives demand for hospitals, medical devices, drugs, and follow-up care, affects reimbursement and procedure volume, and can influence revenue and risk for companies in healthcare and life sciences.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google

An expanded U.S. 510(k) extends the Hugo™ RAS system's reach into one of the fastest-growing areas of U.S. robotic surgery. 

GALWAY, Ireland, Nov. 17, 2026 /PRNewswire/ -- Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced the U.S. Food and Drug Administration (FDA) has cleared the Hugo™ robotic-assisted surgery (RAS) system for use in general surgery procedures.

Medtronic Hugo(TM) RAS system

The clearance covers all upper abdominal general surgical procedures, including but not limited to cholecystectomy, Roux-en-Y gastric bypass, ventral hernia, and small bowel resection. Additionally, lower abdominal procedures of inguinal hernia and appendectomy were cleared. Combined, these procedures account for about 3.5 million surgeries annually in the U.S. — more than half of all soft-tissue procedures performed in the country each year.

This clearance extends the Hugo RAS system's reach into surgical specialties where Medtronic technologies in open and laparoscopic approaches have been used for more than a half century.

"For decades, Medtronic has partnered with general surgeons, and we're bringing that same commitment to robotic surgery for U.S. customers. Hugo expands choice with a practical option to help hospitals address capacity and access challenges, while giving surgical teams more flexibility to meet patients' needs across care settings," said Matt Anderson, senior vice president and president of Medtronic's Surgical business.

The Hugo RAS system is in clinical use at a growing number of health systems and hospitals across the U.S. Globally, Hugo RAS system procedure growth is running at more than two times the robotic surgery market and is on track to surpass 50,000 procedures by the end of the Medtronic fiscal year. General surgery also represents the highest growth for Hugo RAS system procedures outside the U.S., surpassing urology and gynecology.

For U.S. hospitals, the clearance of general surgery procedures expands the range of procedures that can be performed with the Hugo RAS system beyond urology. The system's modular design allows surgical teams flexibility to use only the robotic arms needed for a given procedure, positioning them for their surgical technique and patient's anatomy, while the open console connects the surgeon with the OR team and patient. Surgeons can also use trusted Medtronic technology in their robotic cases, including the LigaSure™ RAS Maryland instrument, which brings vessel-sealing technology used in more than 45 million open and laparoscopic procedures to the Hugo RAS system.

"As an academic health system serving communities across Chicago, our priority is to ensure patients have access to high-quality surgical care and treatment options that best meet their individual needs," said Dr. Francesco Bianco, UI Health surgeon, and professor of surgery at the University of Illinois College of Medicine. "Expanding our robotic-assisted surgical capabilities with the Hugo RAS system allows us to offer additional treatment options, while supporting our commitment to advancing surgical education and training the next generation of surgeons."

Medtronic brings robotics, instruments, data, and expertise together with the goal of making surgery more precise, predictable, and personalized — and more accessible to more patients around the world. Alongside the Hugo RAS system and its connected surgical ecosystem, the company's distribution of the Sentire™* surgical system in select markets outside the U.S., is rooted in that pursuit.

Learn more at medtronic.com/HugoSpecialties.

Medtronic is the sole authorized distributor of Cornerstone Robotic's Sentire™* surgical system outside of the United States. Medtronic, the Medtronic logo, and Engineering the extraordinary are trademarks of Medtronic. ™* Third-party brands are trademarks of their respective owner. All other brands are trademarks of a Medtronic company.

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Galway, Ireland, is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across more than 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic, visit www.Medtronic.com and follow on LinkedIn.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

Contacts:
Gary Jeanfaivre
Public Relations
+1-203-556-0777

Ingrid Goldberg
Investor Relations
+1-763-505-2696

Medtronic plc

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/medtronic-announces-fda-clearance-of-general-surgery-procedures-for-the-hugo-robotic-assisted-surgery-ras-system-302941366.html

SOURCE Medtronic plc

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

Which general surgery procedures did the FDA clear for Medtronic's Hugo system?

The FDA cleared Hugo for all upper abdominal general surgical procedures, plus lower abdominal inguinal hernia procedures and appendectomy. Upper abdominal examples include cholecystectomy, or gallbladder removal, Roux-en-Y gastric bypass, ventral hernia procedures and small bowel resection.

What procedure volume does Medtronic expect for the Hugo robotic surgery system?

Medtronic said global Hugo procedure volume is on track to surpass 50,000 procedures by the end of its fiscal year. Global Hugo procedure growth is running at more than two times the robotic surgery market's growth.

Keep reading